BCL2 and leukemia: Compared to prior studies targeting BCL-2, such as the 10–23 DNAzyme explored by Yang et al. [41], which showed moderate mRNA suppression in leukemia models, our evolved DNZ-15 and DNZ-35a DNAzymes demonstrate improved catalytic efficiency (35% and 30% cleavage, respectively) under near-physiological conditions.